J Wafflart - Concepedia

Author

J Wafflart

Institut Bergonié

Also Known As

J Wafflart, J. WAFFLART, J. Wafflart

Publications

321

Citations

H-Index

Concepts

All Affiliations

Institut Bergonié Hôpital René Huguenin Centre Georges François Leclerc Institut Jean Godinot Institut Claudius Regaud

About

J Wafflart is an author at Institut Bergonié specializing in medicine, oncology, and breast cancer.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	6	6	268
2	Obstetrics	3	3	209
3	Pharmacology	2	2	33
4	Cell Biology	1	1	26
5	Pathology	1	1	26

J Wafflart

Publications

287

Citations

H-Index

Page 1

	Year	Citations
CA 125 half-life and CA 125 nadir during induction chemotherapy are independent predictors of epithelial ovarian cancer outcome: results of a French multicentric study Jean‐Marc Riedinger, J Wafflart, Gabriel Ricolleau, Annals of Oncology Ca 125MedicineCancer ManagementGynecologyFrench Multicentric Study	2006	101
pS2 protein: a marker improving prediction of response to neoadjuvant tamoxifen in post-menopausal breast cancer patients Isabelle Soubeyran, Nathalie Quénel, Jean‐Michel Coindre, British Journal of Cancer Prognostic BiomarkersNeoadjuvant TamoxifenBreast OncologyMedicineGynecology	1996	69
Change in CA 125 levels after the first cycle of induction chemotherapy is an independent predictor of epithelial ovarian tumour outcome J.-M. Riedinger, Franck Bonnetain, J.P. Basuyau, Annals of Oncology Ca 125MedicineIndependent PredictorGynecologyMetronomic Chemotherapy	2007	39
Quantitative determination of c-erbB-2 in human breast tumours: potential prognostic significance of low values Serge Koscielny, P. Terrier, A Daver, European Journal of Cancer Tumor BiologyHuman Breast TumoursBreast OncologyOncologyMedicine	1998	26
Adjuvant trial for stage II receptor-positive breast cancer: CMF vs. CMF+ tamoxifen in a single centre L. Mauriac, M. Durand, J Chauvergne, Breast Cancer Research and Treatment Breast OncologyOncologyAdjuvant TrialCmf+ TamoxifenPharmacology	1988	21
Autoantibodies directed against lipid membrane components in sera of patients with malignant tumors. Sylvie Faiderbe, Chagnaud Jl, Charrier Mc, PubMed	1991	19
Original article: Randomized trial of adjuvant chemotherapy for operable breast cancer comparing i.v. CMF to an epirubicin-containing regimen L. Mauriac, M. Durand, J Chauvergne, Annals of Oncology Surgical OncologyOncologyBreast OncologyPharmacologyClinical Trials	1992	12

Page 1